Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Verona Pharma PLC American Depositary Share (VRNA) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Verona Pharma PLC American Depositary Share (VRNA) - free report >>
Image: Bigstock
Verona Pharma PLC American Depositary Share (VRNA) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Verona Pharma PLC American Depositary Share (VRNA - Free Report) closed at $23.69, marking a -0.96% move from the previous day. This change lagged the S&P 500's daily loss of 0.2%. At the same time, the Dow lost 1.14%, and the tech-heavy Nasdaq gained 1.39%.
Coming into today, shares of the company had gained 77.32% in the past month. In that same time, the Medical sector gained 1.12%, while the S&P 500 gained 4.01%.
Investors will be hoping for strength from Verona Pharma PLC American Depositary Share as it approaches its next earnings release. In that report, analysts expect Verona Pharma PLC American Depositary Share to post earnings of -$0.22 per share. This would mark year-over-year growth of 45%.
Investors should also note any recent changes to analyst estimates for Verona Pharma PLC American Depositary Share. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Verona Pharma PLC American Depositary Share is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 69, putting it in the top 28% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.